Sherlock debuts to develop CRISPR diagnostics with IP from Broad, Harvard
Broad Institute of MIT and Harvard launched CRISPR diagnostic company Sherlock on Thursday with $35 million in funding and exclusive licenses to platforms developed by CRISPR pioneer Feng Zhang and prominent synthetic biologist James Collins.
Sherlock Biosciences Inc. (Cambridge, Mass.) plans to develop inexpensive, paper-based diagnostic tests that can rapidly detect RNA and DNA in a range of settings, including clinical, hospital, low-resource, at-home and point-of-care field settings...